Cerenome's Novel CNS Brachytherapy Faces Existential Runway Crisis Before Any Efficacy Signal

Cerenome Advances CNS Oncology Platform, Reports Q2 2026 Financials

Cerenome announced its second quarter 2026 financial results and provided an overview of recent business highlights. The company rebranded from Plus Therapeutics, Inc. to Cerenome, effective August 3, 2026. Clinical development for REYOBIQ™ progressed with continued enrollment in the ReSPECT-LM and ReSPECT-GBM trials, and initial site activation for the ReSPECT-PBC pediatric brain cancer Phase 1 trial. The CNSide® CSF Assay Platform performed 232 tests in H1 2026 and achieved its 2026 objective of 150 million covered lives through commercial payer coverage. Financially, cash, cash equivalents, and investments stood at $8.6 million as of June 30, 2026. The operating loss for Q2 2026 was $9.1 million, and net loss was $9.0 million, or $1.31 per basic share. Cerenome affirmed its anticipated milestones for 2026, including completing ReSPECT-GBM enrollment and expanding CNSide commercial rollout.

• Corporate Rebranding and Financial Performance: Cerenome successfully rebranded from Plus Therapeutics, Inc. on August 3, 2026, now trading as CNSY on Nasdaq. The company reported $8.6 million in cash, cash equivalents, and investments as of June 30, 2026. For Q2 2026, the operating loss was $9.1 million, and the net loss was $9.0 million, or $1.31 per basic share. This financial performance reflects the expansion of CNSide commercial operations and ongoing funding for the REYOBIQ Phase 2 trial, indicating significant investment in growth and clinical advancement.
• Advancements in REYOBIQ Clinical Trials: Significant progress was made in the REYOBIQ development program. Enrollment continued in the ReSPECT-LM multiple-dose trial, with approximately one-third of patients enrolled and no dose-limiting toxicities, supporting a recommended Phase 2 dose by year-end. The ReSPECT-GBM Phase 2 trial is expected to complete enrollment in 2026, with data anticipated in Q1 2027. Additionally, the ReSPECT-PBC pediatric brain cancer Phase 1 trial initiated site activation at Lurie Children’s Hospital, with first dosing expected in Q3 2026, backed by a $3 million grant from the U.S. Department of Defense.
• Expansion of CNSide® CSF Assay Platform: The CNSide platform demonstrated strong commercial growth, performing 232 cerebrospinal fluid tests during the first half of 2026. Critically, Cerenome achieved its 2026 corporate objective by securing contracted commercial payer coverage for 150 million covered lives by mid-year. Further enhancing its market position, the company received a Medicare Provider Transaction Access Number, achieved CAP accreditation for its CLIA laboratory, and established strategic partnerships with Genomic Testing Cooperative and Xifin, Inc. for next-generation sequencing integration and revenue cycle management.

Addressing the Urgent Unmet Need in Leptomeningeal Metastases

Leptomeningeal metastases (LM) represent one of the most therapeutically intractable manifestations of advanced malignancy, with current treatment modalities constrained by diagnostic imprecision, pharmacological barriers, and an absence of standardized assessment frameworks. Despite incremental advances, median survival following diagnosis remains dismal at 4–7 months (mean overall survival approximately 18.2 weeks), underscoring the urgent need for more effective strategies.

• Diagnostic insensitivity: The clinical presentation of LM is highly variable, and both CSF cytology and contrast-enhanced MRI demonstrate limited sensitivity. Most lesions are nonmeasurable, rendering neuroimaging assessment inherently subjective and hampering reliable disease monitoring.

• Intrathecal chemotherapy limitations: Intrathecal chemotherapy confers only marginal survival benefit, and administration complexity has restricted its widespread adoption. Even with intraventricular delivery via Ommaya reservoir, frequent CSF flow disturbances — manifested as elevated intracranial pressure — result in uneven drug distribution, substantially undermining therapeutic efficacy.

• Inadequate CNS penetration of systemic agents: Achieving therapeutic CSF concentrations through systemic chemotherapy remains largely unattainable, with high-dose intravenous methotrexate representing a notable exception. Intrathecal small-molecule agents penetrate deep brain parenchyma only negligibly, though intrathecal antibodies may offer greater potential for reaching therapeutic concentrations in deeper compartments.

• Lack of standardized response criteria: LM currently lacks consensus frameworks for response assessment. The absence of uniform criteria across clinical trials — including those for medulloblastoma and other leptomeningeal-seeding tumors — complicates evaluation of therapeutic efficacy and limits meaningful cross-study comparisons.

Advancing REYOBIQ in the ReSPECT-LM Clinical Program

The clinical investigation of leptomeningeal metastases (LM) spans a heterogeneous landscape of trial designs, patient populations, and endpoint frameworks — reflecting the complexity of this rare and difficult-to-treat condition. The studies below collectively inform benchmark efficacy expectations, standardized response criteria, and prognostic stratification relevant to emerging programs such as ReSPECT-LM.

Cerenome's Integrated Strategy for Challenging Brain Cancers

Cerenome's recent financial update and strategic rebranding underscore a focused commitment to tackling some of the most challenging conditions in neuro-oncology. The company is advancing a dual strategy, combining a novel therapeutic approach with an innovative diagnostic platform, aiming to redefine care for patients with aggressive brain cancers and leptomeningeal metastasis.

At the heart of their therapeutic pipeline is REYOBIQ™, a radiolabeled nanoliposome designed for convection-enhanced delivery (CED). This approach is critical for bypassing the formidable blood-brain barrier, a major impediment to effective brain tumor treatment. Preclinical studies have shown that rhenium-186 liposomes delivered via CED can achieve high, localized radiation doses within tumors, leading to significant tumor reduction and prolonged survival in models of glioblastoma. The ongoing ReSPECT-LM, ReSPECT-GBM, and ReSPECT-PBC trials are crucial steps in translating this preclinical promise into clinical reality, with image-guided catheter placement offering a path to optimized, patient-specific delivery.

Complementing this therapeutic effort is the CNSide® CSF Assay Platform, a sophisticated diagnostic tool for leptomeningeal metastasis (LM). LM diagnosis has historically been challenging due to the low sensitivity of conventional CSF cytology. CNSide® addresses this by quantifying circulating tumor cells (CTCs) in cerebrospinal fluid, demonstrating significantly higher sensitivity and specificity. This capability is vital for earlier and more accurate diagnosis, which can profoundly impact treatment decisions and patient outcomes. The platform's rapid expansion in commercial payer coverage, now reaching 150 million covered lives, highlights its recognized clinical value and market readiness.

However, this ambitious strategy is not without its considerations. The company's current financial position, marked by a significant operating loss and limited cash reserves, suggests a need for careful financial management and potential future capital raises. Furthermore, while preclinical data for REYOBIQ™ are compelling, the transition to human trials always presents inherent risks regarding safety and demonstrating efficacy in complex patient populations. For CNSide®, despite its diagnostic advantages, widespread clinical adoption will require continued education and integration into existing diagnostic pathways. Ultimately, Cerenome's integrated approach holds substantial promise for patients facing devastating neurological cancers, but successful execution will hinge on navigating these clinical and financial landscapes.